Prescription drug pricing has arguably become the biggest issue in U.S. healthcare. Generic drugs are a very viable solution. Thoroughly convinced of the unbelievable value proposition of their products, the generics industry is working to educate both the public and policymakers about generic/biosimilar drugs in order to restore the country’s balance between generic access and brand-name innovation.
This eBook will explore:
- Generic But Mighty: Generics step up to the plate
- Manufacturing biosimilars: challenges and best-practices
- Excipient trends: addressing bioequivalence and solubility challenges